Trials / Unknown
UnknownNCT04609540
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Pyrotinib Combined With Trastuzumab and Chemotherapy in HER2-positive Metastatic Breast Cancer Patients- a Multicenter Retrospective Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Shandong Cancer Hospital and Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in China, and to explore the relationship between progression free survival and treatment pattern.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab | Dual anti-HER2 therapy |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2021-12-01
- Completion
- 2022-06-01
- First posted
- 2020-10-30
- Last updated
- 2020-12-16
Source: ClinicalTrials.gov record NCT04609540. Inclusion in this directory is not an endorsement.